GoodRx Holdings, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
GoodRx Holdings, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
  • GoodRx Holdings, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was $3.97M.
  • GoodRx Holdings, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$16.2M, a 208% decline year-over-year.
  • GoodRx Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$8.87M, a 73% increase from 2022.
  • GoodRx Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$32.8M, a 30% decline from 2021.
  • GoodRx Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$25.3M, a 91.4% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$16.2M $3.97M +$42.5M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$58.7M $6.69M -$52.1M -88.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$6.59M -$1.01M +$2.28M +69.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$8.87M -$25.9M -$23.9M -1212% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $15M -$38.5M +$3.24M +7.76% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $11.8M $58.8M +$60.2M Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$48.4M -$3.29M -$15.6M -127% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$32.8M -$1.97M +$37.9M +95.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$70.8M -$41.7M -$23.7M -131% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$47.1M -$1.42M -$32.5M -105% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$14.6M $12.3M +$10.6M +637% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$25.3M -$39.9M +$258M +86.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$284M -$18.1M +$32M +63.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$316M $31.1M +$3.72M +13.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$319M $1.67M -$25.7M -93.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$294M -$298M -$314M -2059% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 $19.9M -$50M -$69.7M -355% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $89.5M $27.3M +$7.69M +39.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 $81.8M $27.3M +$15.8M +137% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 $66M $15.2M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $19.6M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $19.7M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 $11.6M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.